Comment: In patents, this leading litigation practice continues to enjoy strong visibility in telecoms cases. FBD defended regular client Apple against the now-settled class action by Nokia, in cooperation with Hogan Lovells – now a well-rehearsed partnership. Both firms were also hired in a suit regarding machinery for manufacturing storage chips for Nikon. In pharmaceuticals proceedings, the team remains active at a high level for Novartis and is landing major new clients too. The trio of partners showed a united front; a series of associate departures in Düsseldorf were thus absorbed by close cooperation with Munich. FBD showed how it is a genuine powerhouse when it comes to recruiting young talent by filling the staffing gaps immediately – incl. with experienced associates from competitors like Hogan Lovells.
Strengths: Litigation, esp. related to pharmaceuticals and telecoms, licensing contracts on the interface with IT, advice on the interface with antitrust.
European strategy: The German team already demonstrates its excellent teamwork with the well-positioned Amsterdam and London patents teams in ongoing client work today, e.g. for Bristol-Myers-Squibb. FBD does not have patent expertise in Paris, instead opting to work in cooperation with the local dispute resolution team to develop general patent litigators for UPC cases – a rather reserved strategy.
Recommended: Prof. Dr. Peter Chrocziel, Dr. Frank-Erich Hufnagel, Wolrad Prinz zu Waldeck und Pyrmont.
Practice: Patents work in Düsseldorf and Munich focuses on litigation, also transactional advice and licenses. Hamburg: licenses and advice to the biotech sector. Clients: predominantly companies from the pharmaceuticals, telecoms and automotive sectors. Close cooperation with ?trademarks and unfair competition, ?antitrust and ?commercial litigation and liability. (Core team: 3 partners, 12 associates)
Clients: ?? Frequent litigation for Apple and Microsoft; Ericsson against TCL and Intellectual Ventures; NTT Docomo against HTC (all regarding mobile communications); Hewlett-Packard regarding large format printers; Nikon against ASML/Carl Zeiss concerning semiconductors (all public knowledge); Continental concerning car tires; Novartis regarding rivastigmine; Bristol-Myers-Squibb regarding Opdivo; Genentech concerning licensing contracts.
  • Teilen